Featured Research

from universities, journals, and other organizations

Protein that inhibits tumor growth discovered

Date:
June 19, 2014
Source:
Cleveland Clinic
Summary:
A previously unknown variant of an extensively studied protein has been found to inhibit the growth of tumors and slow the development of new blood vessels necessary for cancers to metastasize, according to research. "This research is significant because it will open new avenues of angiogenesis and cancer research. It is important for patients as it could potentially lead to new diagnostic tools and improved treatments to reduce the spread of cancer." the lead researcher said.

A previously unknown variant of an extensively studied protein has been found to inhibit the growth of tumors and slow the development of new blood vessels necessary for cancers to metastasize, according to Cleveland Clinic research published in Cell.

The creation of new blood vessels, or angiogenesis, is a vital part of cancer growth and metastasis. Blood vessels carry nutrients and oxygen, which tumors need to survive, expand, and migrate to other parts of the body. A family of proteins called vascular endothelial growth factors (VEGFs) are behind the process of angiogenesis, and one particular protein, VEGF-A, is the principal driver in the process.

However, a research team led by Paul Fox, Ph.D., of the Department of Cellular and Molecular Medicine in Cleveland Clinic's Lerner Research Institute, has discovered that a variant of VEGF-A, one they call VEGF-Ax, actually decreases angiogenesis, cutting off the blood supply to tumors and inhibiting their development in animal models.

"This research is significant because it will open new avenues of angiogenesis and cancer research. It is important for patients as it could potentially lead to new diagnostic tools and improved treatments to reduce the spread of cancer." Dr. Fox said. "It is truly remarkable that a small change in a protein sequence leads not just to a protein with a different function, but one with a function completely opposite to the original. In the context of cancer, the small extension changes a very 'bad' protein into a very 'good' one."

VEGF-Ax is 22 amino acids longer that VEGF-A, and is formed when the ribosome -- the cellular machinery that translates genes (actually messenger RNAs) into proteins -- reads through its genetic stop sign in a process called programmed translational readthrough.


Story Source:

The above story is based on materials provided by Cleveland Clinic. Note: Materials may be edited for content and length.


Journal Reference:

  1. SandeepaM. Eswarappa, AlkaA. Potdar, WilliamJ. Koch, Yi Fan, Kommireddy Vasu, Daniel Lindner, Belinda Willard, LindaM. Graham, PaulE. DiCorleto, PaulL. Fox. Programmed Translational Readthrough Generates Antiangiogenic VEGF-Ax. Cell, 2014; 157 (7): 1605 DOI: 10.1016/j.cell.2014.04.033

Cite This Page:

Cleveland Clinic. "Protein that inhibits tumor growth discovered." ScienceDaily. ScienceDaily, 19 June 2014. <www.sciencedaily.com/releases/2014/06/140619125216.htm>.
Cleveland Clinic. (2014, June 19). Protein that inhibits tumor growth discovered. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/06/140619125216.htm
Cleveland Clinic. "Protein that inhibits tumor growth discovered." ScienceDaily. www.sciencedaily.com/releases/2014/06/140619125216.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins